Post-earnings recap
Reported
Wed, Nov 5, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a better-than-expected EPS, which indicates some operational strength. However, the stock fell by 2.2%, likely due to the lack of revenue information and guidance. Investors may be cautious as they await more clarity on the company's financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.58 | N/A | +10.36% |
| Revenue | N/A | N/A | N/A |
Management highlighted the positive EPS surprise as a sign of operational efficiency. However, they did not provide specific revenue guidance or updates.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing commitment to their strategic goals.